イスラエル - 英語 - Ministry of Health

padagis israel pharmaceuticals ltd, israel - glipizide - tablets - glipizide 5 mg - glipizide - glipizide - is indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with diabetes mellitus type ii

イスラエル - 英語 - Ministry of Health

medison pharma ltd - sapropterin dihydrochloride - tablets soluble - sapropterin dihydrochloride 100 mg - sapropterin - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

イスラエル - 英語 - Ministry of Health

padagis israel pharmaceuticals ltd, israel - bifonazole - gel - bifonazole 1 %w/w - bifonazole - bifonazole - broad spectrum antimycotic agent.

イスラエル - 英語 - Ministry of Health

padagis israel pharmaceuticals ltd, israel - bifonazole - solution - bifonazole 1 %w/v / 100 ml - bifonazole - bifonazole - broad spectrum antimycotic agent.

イスラエル - 英語 - Ministry of Health

padagis israel pharmaceuticals ltd, israel - butenafine hydrochloride - cream - butenafine hydrochloride 1 % - butenafine - butenafine - interdigital tinea pedis, tinea coporis, tinea cruris . (treatment in tinea coporis and tinea cruris is limited to up to 4 weeks).

イスラエル - 英語 - Ministry of Health

ferring pharmaceuticals ltd - quinagolide as hydrochloride - tablets - quinagolide as hydrochloride 0.025 mg - quinagolide - quinagolide - second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).

イスラエル - 英語 - Ministry of Health

ferring pharmaceuticals ltd - quinagolide as hydrochloride - tablets - quinagolide as hydrochloride 0.05 mg - quinagolide - quinagolide - second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).

イスラエル - 英語 - Ministry of Health

ferring pharmaceuticals ltd - quinagolide as hydrochloride - tablets - quinagolide as hydrochloride 0.075 mg - quinagolide - quinagolide - second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).

イスラエル - 英語 - Ministry of Health

ferring pharmaceuticals ltd - quinagolide as hydrochloride - tablets - quinagolide as hydrochloride 0.15 mg - quinagolide - quinagolide - second line treatment of hyperprolactinaemia (idiopathic or due to prolactin secreting micro- or macroadenoma) and its clinical manifestation (galactorrhoea, oligomenorrhea, infertility, reduced libido).

イスラエル - 英語 - Ministry of Health

a. lapidot pharmaceuticals, ltd - mifepristone - tablets - mifepristone 200 mg - mifepristone - mifepristone - medical termination of developing intra-uterine pregnancy.- in sequential use with a prostaglandin analogue up to 63 days of amenorrhea.- softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.- preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester).- labour induction in foetal death in utero.in patients where prostaglandin or oxytocin cannot be use.